Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442] ...

Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma TA1149 30 April 2026 30 April 2026 Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or ...

For decades, the little blue inhaler was a lifeline for millions of people with asthma. But doctors now know it can make the condition worse - and a quiet revolution in treatment is already ...

All NICE products on stomach cancer. Includes any guidance and quality standards.

NICE today announced the appointment of Dr Adrian Hayter as its new chief medical officer, bolstering the institute’s clinical leadership, following the appointment of CEO Professor Jonathan Benger ...

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...

There are commercial access agreements for encorafenib and binimetinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for vorasidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Recommended medicines for weight management and related NICE guidance are shown in table 1. This should be read alongside NHS England's interim commissioning guidance for TA1026. All medicines for ...

Adults with acute ST-segment-elevation myocardial infarction (STEMI) who present within 12 hours of onset of symptoms have primary percutaneous coronary intervention (PCI), as the preferred coronary ...

A commercial access agreement was added to this guidance and the price list for tirzepatide was updated. Next review: This guidance will be reviewed if there is new evidence that is likely to change ...